Patent 11986535 was granted and assigned to NBE Therapeutics on May, 2024 by the United States Patent and Trademark Office.
The present invention relates to a method of producing an immunoligand/payload conjugate, which method encompasses conjugating a payload to an immunoligand by means of a sequence-specific transpeptidase, or a catalytic domain thereof (Fig.